专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20190282644A1 ANTIDIURETIC FORMULATION 审中-公开
公开(公告)号：US20190282644A1
公开(公告)日：2019-09-19
申请号：US16355349
申请日：2019-03-15
申请人： Fei SUN
发明人： Fei SUN
IPC分类号： A61K36/28 , A61K36/57 , A61K36/076 , A61K36/54 , A61K36/884 , A61P13/02
摘要： An exemplary formulation including a specific weight ratio of Atractylodes macrocephala to other certain ingredients surprisingly had an antidiuretic effect which is opposite to what was expected from the common general knowledge. One aspect of such a formulation includes Atractylodes macrocephala; at least one other ingredient that can include at least one of Polyporus umbellatus; Poria cocos; Cinnamomum cassia (twig); and at least one of Alisma orientale and Alisma plantago-aquatica. The formulation can be formed with a weight ratio of Atractylodes macrocephala being greater than 25% with respect to the at least one other ingredient. These formulations may be useful in a method for the treatment of excessive urination, the method including administering an effective amount of a formulation as described herein to a patent in need thereof.

2. 发明授权

US09504690B2 Tetracyclic xanthene derivatives and methods of use thereof for the treatment of viral diseases 有权
标题翻译：四环呫吨衍生物及其用于治疗病毒性疾病的方法
公开(公告)号：US09504690B2
公开(公告)日：2016-11-29
申请号：US14005430
申请日：2012-03-16
申请人： Craig A. Coburn , Stuart B. Rosenblum , Joseph A. Kozlowski , Richard Soll , Hao Wu , Bin Hu , Bin Zhong , Dahai Wang , Changmao Shen , Fei Sun
发明人： Craig A. Coburn , Stuart B. Rosenblum , Joseph A. Kozlowski , Richard Soll , Hao Wu , Bin Hu , Bin Zhong , Dahai Wang , Changmao Shen , Fei Sun
IPC分类号： A61K31/535 , A61K31/5383 , C07D491/06 , C07D498/06 , A61K31/4178 , A61K45/06 , C07D493/06
CPC分类号： A61K31/5383 , A61K31/4178 , A61K45/06 , C07D491/06 , C07D493/06 , C07D498/06
摘要： The present invention relates to novel Tetracyclic Xanthene Derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein A, Y1, Y2, Z, Ra, Rb, R1a, R1b and R2 are as defined herein. The present invention also relates to compositions comprising at least one Tetracyclic Xanthene Derivative, and methods of using the Tetracyclic Xanthene Derivatives for treating or preventing HCV infection in a patient.

3. 发明申请

US20160129077A1 Use of recombinant ganoderma immunoregulatory protein (rLZ-8) in preparation of drug for treating melanoma 审中-公开
标题翻译：使用重组灵芝免疫调节蛋白（rLZ-8）制备治疗黑色素瘤的药物
公开(公告)号：US20160129077A1
公开(公告)日：2016-05-12
申请号：US14907263
申请日：2014-06-13
申请人： Xitian Zhang , Fei Sun
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： A61K38/16
CPC分类号： A61K38/16
摘要： A use of recombinant ganoderma immunoregulatory protein (rLZ-8) in a preparation of a drug for treating melanoma is disclosed. By establishing experimental animal models of orthotopic tumors and metastatic tumors, an anti-tumor effect of the rLZ-8 is researched, which indicates that the rLZ-8 significantly inhibits a growth of the orthotopic tumors of the melanoma and a formation of metastases of the melanoma.
摘要翻译：公开了重组灵芝免疫调节蛋白（rLZ-8）在制备治疗黑素瘤药物中的应用。通过建立原位肿瘤和转移性肿瘤的实验动物模型，研究了rLZ-8的抗肿瘤作用，表明rLZ-8显着抑制黑素瘤原位肿瘤的生长，形成转移瘤黑色素瘤

4. 发明申请

US20110009597A1 RECOMBINANT GANODERMA LUCIDIUM IMMUNOMODULATORY PROTEIN (rLZ-8) AND USES THEREOF 审中-公开
标题翻译：重组GANODERMA LUCIDIUM免疫培养基蛋白（rLZ-8）及其用途
公开(公告)号：US20110009597A1
公开(公告)日：2011-01-13
申请号：US12829653
申请日：2010-07-02
申请人： Fei SUN , Xitian ZHANG
发明人： Fei SUN , Xitian ZHANG
IPC分类号： C07K14/00
CPC分类号： C07K14/37 , A61K38/00 , C07K14/375 , Y02A50/483
摘要： Provided are the use of the recombinant Ganoderma lucidium immunomodulatory protein (rLZ-8) for the manufacturing of a medicament for antitumor, increasing leukocyte and inhibiting immunological rejection and the pharmaceutical composition comprising the rLZ-8 protein, wherein the rLZ-8 protein is expressed from pichia yeast.
摘要翻译：提供了重组灵芝免疫调节蛋白（rLZ-8）用于制造用于抗肿瘤，增加白细胞和抑制免疫排斥的药物的组合物，以及包含rLZ-8蛋白质的药物组合物，其中rLZ-8蛋白质被表达来自毕赤酵母。

5. 发明申请

US20190352345A1 Mutants of recombinant immunoregulatory protein of Ganoderma lucidum and applications thereof 审中-公开
公开(公告)号：US20190352345A1
公开(公告)日：2019-11-21
申请号：US16462941
申请日：2018-03-14
申请人： Xitian Zhang , Fei Sun , Xin Zhang
发明人： Fei Sun , Chongyang Liang
IPC分类号： C07K14/375 , A61P35/00 , A61P35/04
摘要： Mutants of recombinant immunoregulatory protein of Ganoderma lucidum (rLZ-8) and applications thereof are provided. It is found by the present invention that: an anti-EGFR (epidermal growth factor receptor) domain exists in a structure of the rLZ-8; particularly, the domain through positive potential characteristics thereof induces a killing effect to an abnormal EGFR-expressed tumor. Based on the above scientific discovery, with utilizing computational simulation technology, the mutants of the rLZ-8, having better antitumor effects, are obtained.

6. 发明申请

US20150329601A1 Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, preparing method and application thereof 审中-公开
标题翻译：甲氧基聚乙二醇丙酸琥珀酰亚胺酯改性重组灵芝免疫调节蛋白，其制备方法及应用
公开(公告)号：US20150329601A1
公开(公告)日：2015-11-19
申请号：US14814356
申请日：2015-07-30
申请人： Xitian Zhang , Fei Sun
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： C07K14/37
CPC分类号： C07K14/37 , A61K38/00 , A61K38/16 , A61K47/60 , C07K14/375
摘要： Methoxypolyethyleneglycol succinimidyl propionate modified recombinant Ganoderma Lucidum immunoregulatory protein, a preparing method and applications thereof are provided, including: the mPEG-SPA modified rLZ-8; the method for preparing the mPEG-SPA modified rLZ-8 comprising: feeding the rLZ-8 dimer and the mPEG-SPA with the molar ratio of 1:1-1:6 into a 0.1M phosphate buffer with pH 5.0-pH 8.0, and stirring by a magnetic stirrer at a room temperature for 1.0-2.5 h, purifying the product for obtaining a modification product with a purity of 98%; and applications of the mPEG-SPA modified rLZ-8 in preparation of medicine for treating leukopenia due to chemotherapy. Advantages are as follows: the method for preparing the mPEG-SPA modified rLZ-8 is simple, and the product is identical; a half-life of the mPEG-SPA modified rLZ-8 is significantly longer than the half-life of unmodified rLZ-8 (illustrated in the FIG. 2); a minimum effective dosage and time for treating leucopenia are also improved.
摘要翻译：提供了甲氧基聚乙二醇琥珀酰亚胺基丙酸酯改性重组灵芝免疫调节蛋白，其制备方法及应用，包括：mPEG-SPA修饰的rLZ-8; 制备mPEG-SPA修饰的rLZ-8的方法包括：将rLZ-8二聚体和mPEG-SPA以1:1-1:6的摩尔比进料到pH 5.0-pH 8.0的0.1M磷酸盐缓冲液中，并用磁力搅拌器在室温下搅拌1.0-2.5小时，纯化产物，得到纯度为98％的改性产物; 以及mPEG-SPA修饰的rLZ-8在化疗药物治疗白细胞减少症药物中的应用。优点如下：制备mPEG-SPA改性rLZ-8的方法简单，产品相同; mPEG-SPA修饰的rLZ-8的半衰期明显长于未修饰的rLZ-8（如图2所示）的半衰期; 治疗白细胞减少症的最小有效剂量和时间也得到改善。

7. 发明授权

US08762818B1 System and methods for performing decoding error detection in a storage device 失效
标题翻译：用于在存储设备中执行解码错误检测的系统和方法
公开(公告)号：US08762818B1
公开(公告)日：2014-06-24
申请号：US12713520
申请日：2010-02-26
申请人： Fei Sun
发明人： Fei Sun
IPC分类号： H03M13/00
CPC分类号： H03M13/617 , H03M13/1525 , H03M13/1545 , H03M13/2906
摘要： System and methods for performing decoding error detection in a storage device are provided. Data bits of a data polynomial may be retrieved from a storage device. The data bits may be arranged in a first order. Error correction may be performed on the retrieved data bits of the data polynomial to produce an error polynomial based on error correction parity information encoded in the data polynomial. Bits of the error polynomial are arranged in a second order that is reverse to the first order. A first remainder of the error polynomial may be computed based on data bits corresponding to the data polynomial arranged in the second order. An error in the error polynomial may be detected based on the computed first remainder.
摘要翻译：提供了用于在存储设备中执行解码错误检测的系统和方法。可以从存储设备检索数据多项式的数据位。数据位可以以第一顺序排列。可以对所检索的数据多项式的数据位执行误差校正，以基于在数据多项式中编码的纠错奇偶校验信息产生误差多项式。误差多项式的位以与第一级相反的二次排列。可以基于与以二阶排列的数据多项式相对应的数据位来计算误差多项式的第一余数。可以基于计算的第一余数来检测错误多项式中的错误。

8. 发明申请

US20160303189A1 Applications of Recombined Ganoderma Lucidum Immunoregulation Protein in Preparing Drugs for Treating Tissue Fibrosis 审中-公开
标题翻译：复方灵芝免疫调节蛋白在制备药物治疗组织纤维化中的应用
公开(公告)号：US20160303189A1
公开(公告)日：2016-10-20
申请号：US15101395
申请日：2014-06-13
申请人： ZHANG XITIAN , FEI SUN
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： A61K38/16 , A61K36/074
CPC分类号： A61K38/16 , A61K36/074
摘要： Applications of recombined ganoderma lucidum immunoregulation protein (rLZ-8) in preparing drugs for treating tissue fibrosis are provided.
摘要翻译：提供重组灵芝免疫调节蛋白（rLZ-8）在制备治疗组织纤维化的药物中的应用。

9. 发明申请

US20160289280A1 Fusion protein of recombinant ganoderma immunoregulatory protein and human serum albumin, preparation method thereof, and application thereof 审中-公开
标题翻译：重组灵芝免疫调节蛋白融合蛋白及人血清白蛋白及其制备方法及应用
公开(公告)号：US20160289280A1
公开(公告)日：2016-10-06
申请号：US14914258
申请日：2014-07-11
申请人： Xitian ZHANG , Fei SUN
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： C07K14/375 , C07K14/765
CPC分类号： C07K14/375 , A61K36/074 , A61K38/00 , A61K38/16 , A61K38/385 , C07K14/765 , C07K2319/31 , A61K2300/00
摘要： The present invention relates to a field of biological pharmacy, wherein a fusion protein rLZ-8 of a ganoderma immunoregulatory protein and HSA prepared with gene engineering technologies, a preparation method thereof and applications thereof are disclosed. Compared with rLZ-8, a half-life of the fusion protein is prolonged, and biological activity thereof is increased. The fusion protein is applicable to drugs in treatment of leucopenia and anti-tumor.
摘要翻译：本发明涉及一种生物制药领域，其中公开了一种灵芝免疫调节蛋白的融合蛋白rLZ-8和用基因工程技术制备的HSA，其制备方法及其应用。与rLZ-8相比，融合蛋白的半衰期延长，生物活性增加。融合蛋白适用于治疗白细胞减少症和抗肿瘤药物。

10. 发明申请

US20160199439A1 Application of recombinant immunoregulatory protein of ganoderma lucidum in preparation of drug for treating focal cerebral ischemia 审中-公开
标题翻译：灵芝重组免疫调节蛋白在制备治疗局灶性脑缺血的药物中的应用
公开(公告)号：US20160199439A1
公开(公告)日：2016-07-14
申请号：US14912914
申请日：2014-06-13
申请人： Xitian ZHANG , Fei SUN
发明人： Xitian Zhang , Fei Sun , Chongyang Liang
IPC分类号： A61K38/16
CPC分类号： A61K38/168
摘要： An application of a recombinant immunoregulatory protein of ganoderma lucidum (rLZ-8) expressed by Pichia pastoris in a preparation of a drug for treating focal cerebral ischemia is provided. The rLZ-8 is able to treat a neurological function injury, decrease a neurological severity score caused by a cerebral injury and decrease an ED-1 positive cell number, so as to decrease an inflammatory response and inhibit apoptosis.
摘要翻译：提供了由巴斯德毕赤酵母表达的灵芝重组免疫调节蛋白（rLZ-8）在制备治疗局灶性脑缺血的药物中的应用。 rLZ-8能够治疗神经功能损伤，降低脑损伤引起的神经系统严重程度评分，降低ED-1阳性细胞数，减少炎症反应，抑制细胞凋亡。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式